The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | IMROZ trial updates: Isa-VRd versus VRd in patients with NDMM ineligible for transplant
In this video, Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, shares updates from the Phase III IMROZ trial (NCT03319667). This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The IMROZ trial is a large prospective randomized study which compared VRd versus isatuximab with VRd as induction and maintenance with lenalidomide-dexamethasone in one arm and isatuximab-lenalidomide-dexamethasone in the other arm. This study showed that the addition of isatuximab to VRd was associated with significant improvement in progression-free survival, in the depth of response, especially minimal residual disease negativity and also with a trend favoring the survival of patients who received isatuximab-based treatment...
The IMROZ trial is a large prospective randomized study which compared VRd versus isatuximab with VRd as induction and maintenance with lenalidomide-dexamethasone in one arm and isatuximab-lenalidomide-dexamethasone in the other arm. This study showed that the addition of isatuximab to VRd was associated with significant improvement in progression-free survival, in the depth of response, especially minimal residual disease negativity and also with a trend favoring the survival of patients who received isatuximab-based treatment.
Read more...
